Amgen Inc.AMGN

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · amgen.com

Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and markets human therapeutics, focusing on medicines to treat serious illnesses including cancer, cardiovascular disease, bone disease, and neurological disorders. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is one of the world's largest biotechnology companies with a portfolio of marketed products including Enbrel, Otezla, Prolia, XGEVA, and Repatha.

Key ratios

Operating cash flow growth

3.9%TTM

2025 -13.3%2024 35.6%2023 -12.9%

EPS growth

31.6%TTM

2025 88.2%2024 -39.5%2023 3.1%

FCF / Sales

26.7%TTM

2025 22.0%2024 31.1%2023 26.1%

Net margin

23.0%TTM

2025 21.0%2024 12.2%2023 23.8%

ROA

8.7%TTM

2025 7.9%2024 6.4%2023 7.6%

ROE

91.5%TTM

2025 106.1%2024 67.6%2023 135.8%

Revenue growth

9.1%TTM

2025 10.0%2024 18.6%2023 7.1%

Recent news

EU regulator backs revoking Amgen's right to sell rare-disease drug 2026-06-26 · Global Banking & Finance Amgen Defends Rare Disease Drug in FDA Crosshairs 2026-06-12 · MedCity News Amgen to Present New Data Across Rare Autoimmune and Inflammatory Diseases at EULAR 2026 2026-06-03 · PR Newswire

Track AMGN in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer